Pacific Edge (Pacific Edge) EBIT : $-21.74 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Pacific Edge EBIT?

Pacific Edge's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2024 was $-9.93 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-21.74 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pacific Edge's annualized ROC % for the quarter that ended in Mar. 2024 was -395.81%. Pacific Edge's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -507.93%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Pacific Edge's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -97.95%.

Pacific Edge EBIT Historical Data

The historical data trend for Pacific Edge's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Edge EBIT Chart

Pacific Edge Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT

Get a 7-Day Free Trial

-12.02

-12.08

-16.39

-22.19

-22.04

Pacific Edge Semi-Annual Data
	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
EBIT	Get a 7-Day Free Trial															-8.81	-9.68	-12.04	-11.82	-9.93

Competitive Comparison of Pacific Edge's EBIT

For the Diagnostics & Research subindustry, Pacific Edge's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pacific Edge's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pacific Edge's EV-to-EBIT falls into.

Pacific Edge EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-21.74 Mil.

Pacific Edge (OTCPK:PFGTF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pacific Edge's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-19.85 * ( 1 - 0% )	/	( (4.473	+	5.557)	/ 2 )
=	-19.85	/	5.015
=	-395.81 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	45.228	-	3.878	-	( 36.877	-	max(0, 4.192	-	41.979	+	36.877	))
=	4.473

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	39.81	-	4.108	-	( 30.724	-	max(0, 5.059	-	35.204	+	30.724	))
=	5.557

Note: The Operating Income data used here is two times the semi-annual (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Pacific Edge's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-19.85	/	( ( (2.563 + max(1.224, 0))	+	(4.029 + max(-0.934, 0)) )	/	2 )
=	-19.85	/	( ( 3.787	+	4.029 )	/	2 )
=	-19.85	/	3.908
=	-507.93 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3.107	+	0.994	+	1.001)	-	(3.878	+	0	+	0)
=	1.224

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.552	+	1.027	+	0.595)	-	(4.108	+	0	+	8.8817841970013E-16)
=	-0.934

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pacific Edge's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-21.74	/	22.196
	=	-97.95 %

Pacific Edge EBIT Related Terms

Thank you for viewing the detailed overview of Pacific Edge's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacific Edge (Pacific Edge) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pacific Edge Ltd (OTCPK:PFGTF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

PEB:New Zealand PEB:Australia

Address

87 St David Street, P.O. Box 56, Dunedin, STL, NZL, 9016

Website

https://www.pacificedgedx.com

Pacific Edge Ltd is a NewZealand based company involved in developing and commercializing diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. The company operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses world wide; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, New Zealand, and the Rest of the World.